Autosomal Dominant Polycystic Kidney Clinical Trials

20 recruitingLast updated: May 13, 2026

There are 20 actively recruiting autosomal dominant polycystic kidney clinical trials across 16 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include Rochester, Minnesota, United States, London, United Kingdom, Jacksonville, Florida, United States. Updated daily from ClinicalTrials.gov.


Autosomal Dominant Polycystic Kidney Trials at a Glance

20 actively recruiting trials for autosomal dominant polycystic kidney are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Rochester, London, and Jacksonville. Lead sponsors running autosomal dominant polycystic kidney studies include Mayo Clinic, Cantonal Hospital Graubuenden, and AstraZeneca.

Browse autosomal dominant polycystic kidney trials by phase

Treatments under study

About Autosomal Dominant Polycystic Kidney Clinical Trials

Looking for clinical trials for Autosomal Dominant Polycystic Kidney? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autosomal Dominant Polycystic Kidney trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autosomal Dominant Polycystic Kidney clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease
AstraZeneca40 enrolled15 locationsNCT07228364
Recruiting

The German ADPKD Tolvaptan Treatment Registry

ADPKD (Autosomal Dominant Polycystic Kidney Disease)
University of Cologne2,000 enrolled12 locationsNCT02497521
Recruiting
Phase 2

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Autosomal Dominant Polycystic Kidney Disease (ADPKD
Vertex Pharmaceuticals Incorporated24 enrolled40 locationsNCT07161037
Recruiting

RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY

Autosomal Dominant Polycystic Kidney Disease (ADPKD
Fondazione IRCCS Policlinico San Matteo di Pavia30 enrolled1 locationNCT07535385
Recruiting
Phase 3

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Autosomal Dominant Polycystic Kidney Disease
The University of Queensland1,174 enrolled49 locationsNCT04939935
Recruiting
Not Applicable

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

HealthyAtypical Hemolytic Uremic SyndromeMembranoproliferative Glomerulonephritis+1 more
Mario Negri Institute for Pharmacological Research105 enrolled1 locationNCT05996731
Recruiting
Not Applicable

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD
Richard Fatica20 enrolled1 locationNCT07454174
Recruiting
Phase 1

Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Autosomal Dominant Polycystic Kidney Disease (ADPKD
PYC Therapeutics116 enrolled9 locationsNCT06714006
Recruiting
Phase 2

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease
AbbVie240 enrolled75 locationsNCT06902558
Recruiting

A Prospective Observational Study of Foam Sclerotherapy .

Autosomal Dominant Polycystic KidneyRenal CystAutosomal Dominant Polycystic Liver Disease+1 more
Mayo Clinic100 enrolled1 locationNCT04111692
Recruiting

Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease
Mayo Clinic40 enrolled1 locationNCT04344769
Recruiting

NOX4 and Related Biomarkers in ADPKD

Autosomal Dominant Polycystic Kidney Disease
Mayo Clinic60 enrolled1 locationNCT04630613
Recruiting

Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD
King's College London200 enrolled1 locationNCT07260071
Recruiting
Phase 2

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease
Cantonal Hospital Graubuenden40 enrolled2 locationsNCT06435858
Recruiting
Phase 2

Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Jemincare135 enrolled1 locationNCT06800651
Recruiting
Phase 2

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

ObesityAutosomal Dominant Polycystic Kidney
University of Colorado, Denver126 enrolled1 locationNCT06582875
Recruiting

Analysis of Patients With Autosomal Dominant Polycystic Kidney

ADPKDAutosomal Dominant Polycystic Kidney
IRCCS Azienda Ospedaliero-Universitaria di Bologna180 enrolled1 locationNCT06759142
Recruiting
Not Applicable

Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Seoul National University Hospital340 enrolled9 locationsNCT06618638
Recruiting

National Registry of Rare Kidney Diseases

Denys-Drash SyndromeTuberous SclerosisAutosomal Recessive Polycystic Kidney Disease+81 more
UK Kidney Association35,000 enrolled1 locationNCT06065852
Recruiting
Phase 2

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

Autosomal Dominant Polycystic KidneyPolycystic Liver Disease
University Medical Center Groningen36 enrolled2 locationsNCT05478083